MARKET

EGRX

EGRX

Eagle Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

47.50
+0.11
+0.23%
After Hours: 46.97 -0.53 -1.11% 16:11 04/08 EDT
OPEN
47.88
PREV CLOSE
47.39
HIGH
48.15
LOW
45.84
VOLUME
122.92K
TURNOVER
--
52 WEEK HIGH
64.94
52 WEEK LOW
33.80
MARKET CAP
649.77M
P/E (TTM)
47.80
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EGRX stock price target is 50.67 with a high estimate of 59.00 and a low estimate of 46.00.

EPS

EGRX News

More
  • Eagle Pharmaceuticals Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM® Rapid Infusion Liquid Bendamustine Formulation
  • Business Wire · 03/30 11:50
  • Edited Transcript of EGRX earnings conference call or presentation 2-Mar-20 1:30pm GMT
  • Thomson Reuters StreetEvents · 03/24 07:20
  • Eagle Pharma to buyback $160M stock
  • seekingalpha · 03/17 17:57
  • Eagle Pharmaceuticals Announces $160M Buyback, Which Replaces Existing Buyback
  • Reuters · 03/17 11:10

Industry

Pharmaceuticals
+2.77%
Pharmaceuticals & Medical Research
+2.82%

Hot Stocks

Symbol
Price
%Change

About EGRX

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
More

Webull offers kinds of Eagle Pharmaceuticals Inc stock information, including NASDAQ:EGRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EGRX stock news, and many more online research tools to help you make informed decisions.